

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1127230
<b>Application Number:</b>	10597443
<b>Confirmation Number:</b>	1065
<b>Title of Invention:</b>	NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE
<b>First Named Inventor:</b>	Tetsuya NAKAMURA
<b>Customer Number:</b>	23373
<b>Filer:</b>	Peter David Olexy/Deangela Williams
<b>Filer Authorized By:</b>	Peter David Olexy
<b>Attorney Docket Number:</b>	Q95749
<b>Receipt Date:</b>	25-JUL-2006
<b>Filing Date:</b>	
<b>Time Stamp:</b>	18:18:44
<b>Application Type:</b>	U.S. National Stage under 35 USC 371
<b>International Application Number:</b>	PCT/JP05/01168

### Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 1400
RAM confirmation Number	385
Deposit Account	194880
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Transmittal letter	Q95749TRANSMITTAL.pdf	99898	no	2
Warnings:					
Information:					
2		Q95749PREAMD.pdf	125880	yes	21
	Multipart Description				
	Doc Desc		Start	End	
	Preliminary Amendment		1	1	
	Specification		2	2	
	Claims		3	21	
	Applicant Arguments/Remarks Made in an Amendment		21	21	
Warnings:					
Information:					
3		Q95749SPECIFICATION.pdf	753521	yes	239
	Multipart Description				
	Doc Desc		Start	End	
	Specification		1	221	
	Claims		222	238	
	Abstract		239	239	
Warnings:					
Information:					
4	Oath or Declaration filed	q95749DEC.pdf	271520	no	4
Warnings:					
Information:					
5	Information Disclosure Statement (IDS) Filed	Q95749IDSFORM.pdf	59811	no	3
Warnings:					

<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
6	Information Disclosure Statement (IDS) Filed	Q95749ptosb08.pdf	84565	no	1
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
7	Foreign Reference	q95749Indianref.pdf	478964	no	6
<b>Warnings:</b>					
<b>Information:</b>					
8	Foreign Reference	q95749scammelref.pdf	605336	no	8
<b>Warnings:</b>					
<b>Information:</b>					
9	Foreign Reference	q95749wo03Ref.pdf	1411707	no	42
<b>Warnings:</b>					
<b>Information:</b>					
10	Foreign Reference	q95749WO2005.pdf	211968	no	5
<b>Warnings:</b>					
<b>Information:</b>					
11	Foreign Reference	q95749wo2ref.pdf	2740774	no	75
<b>Warnings:</b>					
<b>Information:</b>					
12	Fee Worksheet (PTO-875)	fee-info.pdf	8566	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			6852510		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.